In terms of treatment by subtype, Supplementary Table S2 shows that patients with the Luminal A (27.7%) and Luminal B (22.7%) subtypes of breast cancer received the highest rates of hormone therapy, compared to HER2 (2.7%) and TNBC (1.7%) subtypes, who generally do not qualify for hormone therapy. This evidence concerns the gene ERBB2 and breast cancer.